Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 9/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469985 | 0.90 | PARP1 (0.38) | PARP1SPRDPP4NR1H2NR1H3 | |
| SCHEMBL24469819 | 0.85 | SPR (0.34) | PARP1SPR | |
| SCHEMBL24469768 | 0.85 | SPR (0.34) | PARP1SPR | |
| SCHEMBL24469807 | 0.84 | P2RX3 (0.43) | PARP1SPRLMNAHDAC1 | |
| SCHEMBL24470121 | 0.82 | SPR (0.35) | PARP1SPR | |
| SCHEMBL24469871 | 0.76 | ADAM17 (0.34) | MEN1KMT2ALMNAHDAC1 | |
| SCHEMBL29670401 | 0.76 | NAMPT (0.40) | PARP1SPR | |
| SCHEMBL24484074 | 0.76 | NAMPT (0.40) | PARP1SPR | |
| SCHEMBL24469873 | 0.75 | PDE3B (0.37) | — | |
| SCHEMBL24469986 | 0.73 | PDE3B (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PARP1 2940/4885SPR 3580/4885DPP4 361/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | PARP1 2940/4885SPR 3580/4885DPP4 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.